DCF — MAIMONIDES MEDICAL CENTER
Enterprise Value: $-1.1B
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-1.1B
Enterprise Value
$-355.0M
PV of Cash Flows
$-706.4M
PV of Terminal Value
$-1.1B
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $1.2B | $-55.6M | -5.0% | $-108.0M | $-98.1M |
| Year 2 | $1.3B | $-44.6M | -4.0% | $-98.5M | $-81.4M |
| Year 3 | $1.3B | $-32.8M | -3.0% | $-88.3M | $-66.3M |
| Year 4 | $1.4B | $-27.0M | -2.0% | $-84.2M | $-57.5M |
| Year 5 | $1.4B | $-24.3M | -2.0% | $-83.2M | $-51.7M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-1.1B. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$1.2B
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.050000000374964985
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5